These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Real-world data study in FSHD
Facio Therapies has announced the completion of a ‘real-world data’ study monitoring the progression of FSHD and its impact on daily life.
Read more-
£1.2m invested in 9 new research projects for 2019
02/09/2019Muscular Dystrophy UK is investing £1.2 million into 9 new research projects this year, bringing our total research portfolio to over £10m.
-
Scientists make ground-breaking discovery on FSHD gene
19/07/2019Scientists from Fred Hutchinson Cancer Research Center (USA) have identified a new role for DUX4, the gene that is mutated in FSHD
-
Highlights from the 2019 FSH Society International Research Congress
15/07/2019The FSH Society International Research Congress was held in France, on 19-20 June 2019
-
Fulcrum repurpose drug for FSHD
24/04/2019Fulcrum Therapeutics has obtained rights to losmapimod from GSK. Fulcrum is interested in the drug because it has found that it can switch off DUX4 in FSHD cells.
-
Update from FSHD drug screening programme
21/03/2019Facio Therapies announced today that it has completed a comprehensive search for new FSHD drug candidates.
-
New FSHD mouse model treated with gene therapy
26/11/2018A recent study has demonstrated the value of a new mouse model of facioscapulohumeral muscular dystrophy (FSHD).
-
Update on FSHD drug development programme
01/11/2018Facio Therapies has shown that one of its lead compounds can reduce the levels of DUX4 in a mouse model.
-
Update on FSHD drug development programme
11/09/2018Facio Therapies has announced that it has selected several compounds as lead candidates for its FSHD drug development programme.
-
ACE-083 is awarded US Orphan Drug Designation
13/07/2018Acceleron has announced the FDA has granted Orphan Drug Designation to ACE-083 for the treatment of FSHD.
-
FSHD drug awarded US Orphan Drug Designation
01/06/2018Genea Biocells has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to GBC0905 for the treatment of FSHD.